老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Braveheart Bio
27.45
+0.7400
2.77%
盤後:
27.45
0.0000
0.00%
16:10 EDT
成交量:
55.07萬
成交額:
1,518.97萬
市值:
24.72億
市盈率:
-1.87
高:
28.90
開:
26.82
低:
26.22
收:
26.71
52周最高:
32.00
52周最低:
24.31
股本:
9,003.90萬
流通股本:
2,583.17萬
量比:
2.02
換手率:
2.13%
股息:
- -
股息率:
- -
每股收益(TTM):
-14.6845
每股收益(LYR):
-17.2003
淨資產收益率:
--
總資產收益率:
--
市淨率:
-25.77
市盈率(LYR):
-1.60
資料載入中...
總覽
公司
新聞資訊
公告
公司資料
公司名字:
Braveheart Bio
交易所:
NASDAQ
成立時間:
2024
員工人數:
49
公司地址:
One Letterman Drive,Building A,Suite A4-300,San Francisco,California,United States
官網:
http://www.braveheart.bio
郵編:
94129
電話:
415 707 6312
傳真:
- -
簡介:
Braveheart Bio, Inc.於2024年5月13日根據特拉華州法律註冊成立。該公司是一家臨床階段的生物製藥公司,專註於為肥厚型心肌病和其他嚴重心血管疾病患者開發療法。其主導候選產品BHB-1893是一種下一代口服小分子心肌肌球蛋白抑製劑,由江蘇恆瑞醫藥有限公司獲得全球授權,不包括大中華區,並已在恆瑞主要在中國和澳大利亞進行的臨床試驗中進行評估。
董事
名稱
職位
Christopher Viehbacher
Chairman of the Board and Director
Travis Murdoch
Chief Executive Officer, President and Director
David C. Lubner
Director
David Malek
Director
Erez Chimovits
Director
Jason Coloma
Director
Jasper Bos
Director
Tim Lohoff
Director
Vineeta Agarwala
Director
股東
名稱
職位
Travis Murdoch
Chief Executive Officer, President and Director
J. Paul Rickey
Chief Financial Officer
Emil deGoma
Chief Medical Officer
Marc Evanchik
Chief Scientific Officer
Michele Anderson
Chief Development Officer
Tyler Chavez
Chief Business Officer
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BRVE/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BRVE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":27.45,"timestamp":1789588800000,"preClose":26.71,"halted":0,"volume":550667,"hourTrading":{"tag":"盘后","latestPrice":27.45,"preClose":27.45,"latestTime":"16:10 EDT","volume":29198,"amount":801485.1,"timestamp":1789589404708,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02770497940846119,"floatShares":25831738,"shares":90039000,"eps":-14.684527,"marketStatus":"盤後交易","change":0.74,"latestTime":"09-16 19:17:19 EDT","open":26.82,"high":28.9,"low":26.22,"amount":15189732,"amplitude":0.100337,"askPrice":30,"askSize":7,"bidPrice":26.76,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-14.684527,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":26.71,"postHourTrading":{"tag":"盘后","latestPrice":27.45,"preClose":27.45,"latestTime":"16:10 EDT","volume":29198,"amount":801485.1,"timestamp":1789589404708,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.019471},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","floatShares":25831738,"roa":"--","roe":"--","lyrEps":-17.200311,"volumeRatio":2.01949,"shares":90039000,"dividePrice":0,"high":28.9,"amplitude":0.100337,"preClose":26.71,"low":26.22,"week52Low":24.305,"pbRate":"-25.77","week52High":32,"institutionHeld":0,"latestPrice":27.45,"committee":-0.666667,"eps":-14.684527,"divideRate":0,"volume":550672,"delay":0,"ttmEps":-14.684527,"open":26.82,"prevYearClose":18,"prevWeekClose":26.64,"prevMonthClose":25.5,"prevQuarterClose":18,"fiveDayClose":28.91,"twentyDayClose":26.75,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRVE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRVE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1788926400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRVE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRVE","date":"2026-09-15","current":-1.869315,"percent":0.892857,"low":-23.993466,"twenty":-22.153967,"median":-21.55413,"eighty":-19.825756,"high":-12.297967,"avg":-20.784414,"sd":2.540276,"marketCap":1733844353},"quantilePoints":[{"date":"2026-08-07","current":-22.904964,"twenty":-19.277064,"median":-13.835213,"eighty":-12.912865,"marketCap":1837733965},{"date":"2026-08-14","current":-20.770344,"twenty":-22.55018,"median":-20.842324,"eighty":-16.302149,"marketCap":1666466982},{"date":"2026-08-21","current":-21.930028,"twenty":-22.591769,"median":-21.618113,"eighty":-20.309669,"marketCap":1759511923},{"date":"2026-08-28","current":-22.281932,"twenty":-22.249941,"median":-22.006007,"eighty":-20.827928,"marketCap":1787746250},{"date":"2026-09-04","current":-21.010278,"twenty":-22.169963,"median":-21.930028,"eighty":-20.827928,"marketCap":1685717659},{"date":"2026-09-11","current":-18.437402,"twenty":-22.185958,"median":-21.618113,"eighty":-20.469626,"marketCap":1748603206},{"date":"2026-09-15","current":-18.281784,"twenty":-22.153967,"median":-21.55413,"eighty":-19.825756,"marketCap":1733844353}],"updateTime":1789600639334},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1959705903,"yearFounded":2024,"employeeNum":49,"address":"One Letterman Drive,Building A,Suite A4-300,San Francisco,California,United States","zipCode":"94129","officePhone":"415 707 6312","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.braveheart.bio","stockEarnings":[{"period":"1week","weight":-0.0918},{"period":"1month","weight":-0.0118},{"period":"3month","weight":0.4839},{"period":"ytd","weight":0.4839}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":-0.0244},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.1479},{"period":"1year","weight":0.146},{"period":"ytd","weight":0.1107}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Braveheart Bio, Inc.於2024年5月13日根據特拉華州法律註冊成立。該公司是一家臨床階段的生物製藥公司,專註於為肥厚型心肌病和其他嚴重心血管疾病患者開發療法。其主導候選產品BHB-1893是一種下一代口服小分子心肌肌球蛋白抑製劑,由江蘇恆瑞醫藥有限公司獲得全球授權,不包括大中華區,並已在恆瑞主要在中國和澳大利亞進行的臨床試驗中進行評估。","exchange":"NASDAQ","name":"Braveheart Bio","nameEN":"Braveheart Bio"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":{"directors":[{"name":"Christopher Viehbacher","position":"Chairman of the Board and Director"},{"name":"Travis Murdoch","position":"Chief Executive Officer, President and Director"},{"name":"David C. Lubner","position":"Director"},{"name":"David Malek","position":"Director"},{"name":"Erez Chimovits","position":"Director"},{"name":"Jason Coloma","position":"Director"},{"name":"Jasper Bos","position":"Director"},{"name":"Tim Lohoff","position":"Director"},{"name":"Vineeta Agarwala","position":"Director"}],"executives":[{"name":"Travis Murdoch","position":"Chief Executive Officer, President and Director"},{"name":"J. Paul Rickey","position":"Chief Financial Officer"},{"name":"Emil deGoma","position":"Chief Medical Officer"},{"name":"Marc Evanchik","position":"Chief Scientific Officer"},{"name":"Michele Anderson","position":"Chief Development Officer"},{"name":"Tyler Chavez","position":"Chief Business Officer"}]}}}